Literature DB >> 30837320

LRRK2 links genetic and sporadic Parkinson's disease.

Jillian H Kluss1, Adamantios Mamais1, Mark R Cookson2.   

Abstract

The past two decades in research has revealed the importance of leucine-rich repeat kinase 2 (LRRK2) in both monogenic and sporadic forms of Parkinson's disease (PD). In families, mutations in LRRK2 can cause PD with age-dependent but variable penetrance and genome-wide association studies have found variants of the gene that are risk factors for sporadic PD. Functional studies have suggested that the common mechanism that links all disease-associated variants is that they increase LRRK2 kinase activity, albeit in different ways. Here, we will discuss the roles of LRRK2 in areas of inflammation and vesicular trafficking in the context of monogenic and sporadic PD. We will also provide a hypothetical model that links inflammation and vesicular trafficking together in an effort to outline how these pathways might interact and eventually lead to neuronal cell death. We will also highlight the translational potential of LRRK2-specific kinase inhibitors for the treatment of PD.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Parkinson's disease; genome-wide association studies; leucine-rich repeat kinase

Mesh:

Substances:

Year:  2019        PMID: 30837320      PMCID: PMC6563926          DOI: 10.1042/BST20180462

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  111 in total

1.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.

Authors:  Manabu Funayama; Kazuko Hasegawa; Etsuro Ohta; Noriko Kawashima; Masaru Komiyama; Hisayuki Kowa; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

2.  Genetics of Parkinson's disease: LRRK2 on the rise.

Authors:  Alexis Brice
Journal:  Brain       Date:  2005-12       Impact factor: 13.501

3.  Clinical and pathological characteristics of LRRK2 G2019S patients with PD.

Authors:  Markos Poulopoulos; Etty Cortes; Jean-Paul G Vonsattel; Stanley Fahn; Cheryl Waters; Lucien J Cote; Carol Moskowitz; Lawrence S Honig; Lorraine N Clark; Karen S Marder; Roy N Alcalay
Journal:  J Mol Neurosci       Date:  2011-12-23       Impact factor: 3.444

Review 4.  Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2016-12-15       Impact factor: 5.407

5.  Test for LRRK2 mutations in patients with Parkinson's disease.

Authors:  D G Healy; N W Wood; A H V Schapira
Journal:  Pract Neurol       Date:  2008-12

6.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.

Authors:  Michael A Nalls; Vincent Plagnol; Dena G Hernandez; Manu Sharma; Una-Marie Sheerin; Mohamad Saad; J Simón-Sánchez; Claudia Schulte; Suzanne Lesage; Sigurlaug Sveinbjörnsdóttir; Kári Stefánsson; Maria Martinez; John Hardy; Peter Heutink; Alexis Brice; Thomas Gasser; Andrew B Singleton; Nicholas W Wood
Journal:  Lancet       Date:  2011-02-01       Impact factor: 79.321

7.  G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.

Authors:  Tatiana D Papkovskaia; Kai-Yin Chau; Francisco Inesta-Vaquera; Dmitri B Papkovsky; Daniel G Healy; Koji Nishio; James Staddon; Michael R Duchen; John Hardy; Anthony H V Schapira; J Mark Cooper
Journal:  Hum Mol Genet       Date:  2012-06-26       Impact factor: 6.150

8.  LRRK2 levels in immune cells are increased in Parkinson's disease.

Authors:  D A Cook; G T Kannarkat; A F Cintron; Laura M Butkovich; Kyle B Fraser; J Chang; N Grigoryan; S A Factor; Andrew B West; J M Boss; M G Tansey
Journal:  NPJ Parkinsons Dis       Date:  2017-03-28

9.  Crystal structure of the WD40 domain dimer of LRRK2.

Authors:  Pengfei Zhang; Ying Fan; Heng Ru; Li Wang; Venkat Giri Magupalli; Susan S Taylor; Dario R Alessi; Hao Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-11       Impact factor: 11.205

10.  Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.

Authors:  Claire Hoenen; Audrey Gustin; Cindy Birck; Mélanie Kirchmeyer; Nicolas Beaume; Paul Felten; Luc Grandbarbe; Paul Heuschling; Tony Heurtaux
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

View more
  51 in total

1.  G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.

Authors:  Nicolas Arbez; XiaoFei He; Yong Huang; Mark Ren; Yideng Liang; Frederick C Nucifora; Xiaofang Wang; Zhong Pei; Lino Tessarolo; Wanli W Smith; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

Review 2.  LRRK2 and idiopathic Parkinson's disease.

Authors:  Emily M Rocha; Matthew T Keeney; Roberto Di Maio; Briana R De Miranda; J Timothy Greenamyre
Journal:  Trends Neurosci       Date:  2022-01-04       Impact factor: 13.837

3.  Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia.

Authors:  Adamantios Mamais; Jillian H Kluss; Luis Bonet-Ponce; Natalie Landeck; Rebekah G Langston; Nathan Smith; Alexandra Beilina; Alice Kaganovich; Manik C Ghosh; Laura Pellegrini; Ravindran Kumaran; Ioannis Papazoglou; George R Heaton; Rina Bandopadhyay; Nunziata Maio; Changyoun Kim; Matthew J LaVoie; David C Gershlick; Mark R Cookson
Journal:  PLoS Biol       Date:  2021-12-16       Impact factor: 8.029

Review 4.  Parkinson's disease and microRNAs - Lessons from model organisms and human studies.

Authors:  Brian Evans; Howard A Furlong; Alexandre de Lencastre
Journal:  Exp Gerontol       Date:  2021-10-08       Impact factor: 4.032

Review 5.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

6.  The parkin-coregulated gene product PACRG promotes TNF signaling by stabilizing LUBAC.

Authors:  Jens Meschede; Maria Šadić; Nikolas Furthmann; Tim Miedema; Dominik A Sehr; A Kathrin Müller-Rischart; Verian Bader; Lena A Berlemann; Anna Pilsl; Anita Schlierf; Katalin Barkovits; Barbara Kachholz; Katrin Rittinger; Fumiyo Ikeda; Katrin Marcus; Liliana Schaefer; Jörg Tatzelt; Konstanze F Winklhofer
Journal:  Sci Signal       Date:  2020-02-04       Impact factor: 8.192

7.  Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

Authors:  Marta San Luciano; Caroline M Tanner; Cheryl Meng; Connie Marras; Samuel M Goldman; Anthony E Lang; Eduardo Tolosa; Birgitt Schüle; J William Langston; Alexis Brice; Jean-Christophe Corvol; Stefano Goldwurm; Christine Klein; Simone Brockman; Daniela Berg; Kathrin Brockmann; Joachim J Ferreira; Meriem Tazir; George D Mellick; Carolyn M Sue; Kazuko Hasegawa; Eng King Tan; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2020-07-14       Impact factor: 10.338

8.  The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.

Authors:  Briana R De Miranda; Sandra L Castro; Emily M Rocha; Christopher R Bodle; Katrina E Johnson; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2021-02-23       Impact factor: 5.996

9.  Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pT73 Rab10.

Authors:  Xiang Wang; Elvira Negrou; Michael T Maloney; Vitaliy V Bondar; Shan V Andrews; Manuel Montalban; Ceyda Llapashtica; Romeo Maciuca; Hoang Nguyen; Hilda Solanoy; Annie Arguello; Laralynne Przybyla; Nathan J Moerke; Sarah Huntwork-Rodriguez; Anastasia G Henry
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

10.  Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.

Authors:  Barbara Calamini; Nathalie Geyer; Nathalie Huss-Braun; Annie Bernhardt; Véronique Harsany; Pierrick Rival; May Cindhuchao; Dietmar Hoffmann; Sabine Gratzer
Journal:  Dis Model Mech       Date:  2021-06-11       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.